Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer

被引:77
|
作者
De Jaeger, K
Seppenwoolde, Y
Boersma, LJ
Muller, SH
Baas, P
Belderbos, JSA
Lebesque, JV
机构
[1] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Chest Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
pulmonary function; SPECT; perfusion; tumor response; mean lung dose;
D O I
10.1016/S0360-3016(02)04389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion. Methods and Materials: Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEVt] and diffusion capacity [T-L,T-COc]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes. Results: In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV1 (p = 0.02), but was associated with a reduction of T-L,T-COc. (P = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs. Conclusion: The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV1 and a decline of T-L,T-COc. Reperfusion was not associated with an improvement of global pulmonary function. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:1331 / 1340
页数:10
相关论文
共 50 条
  • [1] High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer
    Allena, Aaron M.
    Shochat, Tzippy
    Flex, Dov
    Kramer, Mordechai R.
    Zer, Alona
    Peled, Nir
    Dudnik, Elizabeta
    Fenig, Eyal
    Saute, Milton
    ONCOLOGY, 2018, 95 (01) : 13 - 19
  • [2] High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer
    De Ruysscher, Dirk
    Faivre-Finn, Corinne
    Le Pechoux, Cecile
    Peeters, Stephanie
    Belderbos, Jose
    LANCET ONCOLOGY, 2014, 15 (13): : E620 - E624
  • [3] High-dose radiotherapy for non-small-cell lung cancer: how high can we go?
    Belderbos, JSA
    De Jaeger, K
    LUNG CANCER, 2004, 45 : S21 - S21
  • [4] Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancer
    Schaafsma, J
    Coy, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 691 - 701
  • [5] TREATMENT OF NON-SMALL-CELL LUNG-CANCER WITH EXTERNAL BEAM RADIOTHERAPY AND HIGH-DOSE RATE BRACHYTHERAPY
    AYGUN, C
    WEINER, S
    SCARIATO, A
    SPEARMAN, D
    STARK, L
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01): : 127 - 132
  • [6] Palliative radiotherapy for non-small-cell lung cancer: Which dose?
    Hoskin, PJ
    CLINICAL ONCOLOGY, 2005, 17 (01) : 59 - 60
  • [7] ACTIVITY OF HIGH-DOSE EPIRUBICIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER
    MARTONI, A
    MELOTTI, B
    GUARALDI, M
    PANNUIT, F
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (10) : 1231 - 1234
  • [8] Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib
    Dhruva, Nirav
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : E31 - E32
  • [9] High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer
    Sura, Sonal
    Yorke, Ellen
    Jackson, Andrew
    Rosenzweig, Kenneth E.
    CANCER JOURNAL, 2007, 13 (04): : 238 - 242
  • [10] High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer
    De Ruysscher, D.
    Reymen, B.
    Van Baardwijk, A.
    MINERVA CHIRURGICA, 2011, 66 (04) : 341 - 345